Compare Frontline Plc Ordinary Shares (FRO) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Frontline Plc Ordinary Shares vs Repligen Corporation Common Stock — how do they compare? Frontline Plc Ordinary Shares trades at $54.93 (market cap $13.14B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Frontline Plc Ordinary Shares is the larger of the two by market cap, and Frontline Plc Ordinary Shares pays a 9.11% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Frontline Plc Ordinary Shares for 1 Days and Repligen Corporation Common Stock for 0 Days on average.
| FRO | RGEN | |
|---|---|---|
Market Cap | $13.14B | $11.14B |
Volume | 3,351,547 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $59.19 | $194.57 |
52-Week Low | $20.58 | $102.87 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $15.26B | $11.02B |
Dividend Yield | 9.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Frontline (FRO) trades at $59.04, down 0.25% on the day, but maintains a strong technical and fundamental position. The stock is near its 52-week high, supported by bullish moving averages and robust earnings, with Q2 2026 EPS beating estimates at $2.96. Revenue and profitability have surged, with 2026 net income margin projected at 54.75%. Recent news highlights a special dividend declaration and institutional buying interest.
The outlook for FRO is positive, driven by record earnings and favorable shipping market dynamics. Investment opportunities include strong cash flow generation and shareholder returns, but risks involve exposure to volatile freight rates and geopolitical tensions affecting global trade. Analyst sentiment is mixed, with a 'Hold' consensus suggesting cautious optimism amid near-term highs.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Frontline Plc Ordinary Shares
Frontline operates a fleet of oil tankers that transport crude oil by sea. Its vessels serve global energy trading routes.
Read more on FRO →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
